Ivytan AB, which is indirectly owned by EQT and Lyftet Holding, has made a cash offer for Swedish biotechnology firm Q-Med valuing the business at SEK 3.9bn. The bid is priced at SEK 39 per Q-Med share - a 24% premium to the closing price on 31 October.
Latest co-mingled vehicle is around a third larger than previous two programmes in the series
Deal with MidEuropa sealed after auction for ophthalmology group went quiet earlier this month
Vendor Horizon collected offers for the agricultural information services provider last week
Multi-family office will doubling down on manager selectivity, opportunities in secondaries, and family offices' interest in increasing PE exposure